Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease

被引：78

作者：

Cavedo, Enrica ^{[1
,2
,3
,4
]}

Grothe, Michel J. ^{[5
,6
]}

Colliot, Olivier ^{[7
,8
]}

Lista, Simone ^{[1
,2
,3
]}

Chupin, Marie ^{[7
,9
]}

Dormont, Didier ^{[7
,10
]}

Houot, Marion ^{[11
]}

Lehericy, Stephane ^{[12
,13
,14
]}

Teipel, Stefan ^{[5
,6
]}

Dubois, Bruno ^{[2
,3
]}

Hampel, Harald ^{[1
,2
,3
]}

机构：

[1] AXA Res Fund & UPMC Chair, Paris, France

[2] Pierre & Marie Curie Univ, Sorbonne Univ, Inst Memory & Alzheimers Dis IM2A, Paris 06, Paris, France

[3] Hop La Pitie Salpetriere, Brain & Spine Inst ICM, UMR S1127, Dept Neurol, Paris, France

[4] IRCCS Ctr San Giovanni Dio Fatebenefratelli, Lab Alzheimers Neuroimaging & Epidemiol, Brescia, Italy

[5] German Ctr Neurodegenerat Dis DZNE Rostock Greifs, Rostock, Germany

[6] Univ Rostock, Dept Psychosomat Med, Rostock, Germany

[7] UPMC Univ Paris 06, Sorbonne Univ, AP HP Hop Pitie Salpetriere, INSERM,CNRS,Inst Cerveau & Moelle ICM, Paris, France

[8] Ctr Rech, INRIA, Aramis Project Team, Paris, France

[9] CATI, Paris, France

[10] Hop La Pitie Salpetriere, AP HP, Neuroradiol Dept, Paris, France

[11] Univ Paris 06, Hop Pitie Salpetriere, APHP Dept Neurol,ICM, Inst Memory & Alzheimers Dis IM2A,Ctr Excellence, Paris, France

[12] Hop La Pitie Salpetriere, CENIR, Paris, France

[13] Inst Cerveau & Moelle Epiniere ICM, INSERM U1127, Paris, France

[14] Univ Pierre & Marie Curie Paris 6, Sorbonne Univ, Paris, France

来源：

SCIENTIFIC REPORTS | 2017年 / 7卷

关键词：

NUCLEUS BASALIS; CHOLINERGIC INNERVATION; SUBSTANTIA INNOMINATA; COGNITIVE IMPAIRMENT; APOE GENOTYPE; RESTING-STATE; BRAIN; PREDICTS; MRI; ACETYLCHOLINESTERASE;

D O I：

10.1038/s41598-017-09780-3

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

070301 [无机化学]; 070403 [天体物理学]; 070507 [自然资源与国土空间规划学]; 090105 [作物生产系统与生态工程];

摘要：

Acetylcholinesterase inhibitors are approved drugs currently used for the treatment of Alzheimer's disease (AD) dementia. Basal forebrain cholinergic system (BFCS) atrophy is reported to precede both entorhinal cortex atrophy and memory impairment in AD, challenging the traditional model of the temporal sequence of topographical pathology associated with AD. We studied the effect of one-year Donepezil treatment on the rate of BFCS atrophy in prodromal AD patients using a double-blind, randomized, placebo-controlled trial of Donepezil (10 mg/day). Reduced annual BFCS rates of atrophy were found in the Donepezil group compared to the Placebo treated arm. Secondary analyses on BFCS subregions demonstrated the largest treatment effects in the Nucleus Basalis of Meynert (NbM) and the medial septum/diagonal band (Ch1/2). Donepezil administered at a prodromal stage of AD seems to substantially reduce the rate of atrophy of the BFCS nuclei with highest concentration of cholinergic neurons projecting to the cortex (NbM), hippocampus and entorhinal cortex (Ch1/2).

引用

页数：10

共 64 条

[1]

[Anonymous], 2015, NEUROIMMUNOL NEUROIN

[2]

CORRELATION BETWEEN CORTICAL PLAQUE COUNT AND NEURONAL LOSS IN THE NUCLEUS BASALIS IN ALZHEIMERS-DISEASE [J].